A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

NCT06335355 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

401

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG: Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin
DRUG: Camrelizumab + Pemetrexed + Carboplatin
DRUG: Adebrelimab + Pemetrexed + Carboplatin

Sponsor

Shanghai Shengdi Pharmaceutical Co., Ltd